Research programme: nucleic acid therapeutics - Mebiopharm

Drug Profile

Research programme: nucleic acid therapeutics - Mebiopharm

Latest Information Update: 26 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mebiopharm
  • Class Anti-infectives; Antibacterials; Antineoplastics; Nucleic acids
  • Mechanism of Action Protein serine threonine kinase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Infections

Most Recent Events

  • 25 May 2016 Early research in Cancer in Japan (unspecified route)
  • 25 May 2016 Mebiopharm receives AMED grant from Japan Agency for Medical Research and Development for drug development in Infections
  • 25 May 2016 Early research in Infections in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top